Sung Young Kim

PHGDH inhibition overcomes dabrafenib resistance through metabolic rewiring in BRAF V600E anaplastic thyroid carcinoma

Abstract Dabrafenib, a BRAF kinase inhibitor, is used clinically to treat anaplastic thyroid carcinoma (ATC) harboring the BRAF V600E mutation. However, its clinical efficacy is limited due to the rapid emergence of resistance to treatment. In this study, we established a dabrafe...